Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01510067 · ClinicalTrials.gov registry record
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
A clinical trial of Cutaneous Lupus Erythematosus (CLE), sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 700
- Enrollment target
- 2
- Study locations
NCT01510067 is a study of Cutaneous Lupus Erythematosus (CLE) that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 700 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01510067, a study of Cutaneous Lupus Erythematosus (CLE), is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 2
- Study locations
Study Summary
The Cutaneous Lupus Erythematosus (CLE) database, established in 2006, is a multi-site database between the University of Pennsylvania and the University of Texas Southwestern (UTSW).
Conditions Studied
Study Locations (2)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2006-12 |
| Est. Completion | 2030-01-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01510067
The ClinicalTrials.gov registry entry for NCT01510067 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Lupus Erythematosus (CLE) appearing as the primary indexed condition, and to 0 interventions.
NCT01510067 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT01510067 about?
NCT01510067 is a clinical study titled "Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus". The Cutaneous Lupus Erythematosus (CLE) database, established in 2006, is a multi-site database between the University of Pennsylvania and the University of Texas Southwestern (UTSW).
What is the current status of trial NCT01510067?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2006-12. Estimated completion is 2030-01-02.
What conditions does trial NCT01510067 study?
This clinical trial studies the following conditions: Cutaneous Lupus Erythematosus (CLE).
Who is sponsoring clinical trial NCT01510067?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01510067 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Lupus Erythematosus (CLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Research Accelerated by You Lupus Registry
RECRUITING
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.